Background and objective: Chronic respiratory failure (CRF) with hypoxaemia is an important pathophysiology in patients with chronic obstructive pulmonary disease (COPD), and existing mild hypoxaemia may be a sign of future CRF development. However, little is known about the trajectory of partial arterial pressure of oxygen (PaO 2 ) decline in patients with COPD. We assessed decline in PaO 2 and the impact of short-term reductions in PaO 2 to predict future decline in PaO 2 . Methods: A total of 172 outpatients with COPD from a prospective cohort study were enrolled. Pulmonary function tests and arterial blood gas (ABG) analyses were conducted at baseline and 1 year after enrolment and changes in PaO 2 (ΔPaO 2 ) and other parameters were calculated. Survival and incidence of CRF (as assessed by prescription of long-term home oxygen therapy) were monitored for 6 years. Results: A total of 164 patients completed the observation period and 101 patients had mild hypoxaemia (PaO 2 < 80 Torr) at baseline. No patients with normal PaO 2 (≥80 Torr) developed CRF, and 10 patients with mild hypoxaemia developed CRF in 6 years. Baseline airflow limitation and diffusion capacity were significantly associated with development of CRF. Receiveroperating characteristic curve analysis showed that ΔPaO 2 of −3.05 Torr/year is a useful cut-off value to predict development of CRF in 6 years (hazard ratio (HR): 12.6, 95% CI: 3.48-58.73, P < 0.0001). Conclusion: Patients with COPD and mild hypoxaemia may benefit from repeat ABG after 1 year. Although PaO 2 trajectories widely varied, significant annual changes in PaO 2 of at least −3.0 Torr/year were predictive of CRF development.
INTRODUCTION
Chronic respiratory failure (CRF) with hypoxaemia impairs activities of daily living (ADL) and leads to poor outcomes in patients with chronic obstructive pulmonary disease (COPD). 1 Long-term oxygen therapy (LTOT) is an effective therapy; however, this therapy remains problematic due to its high cost and its deleterious impact on patient lifestyles and quality of life. [2] [3] [4] [5] [6] As CRF is rarely reversible, preventing disease progression is essential for the management of patients with
SUMMARY AT A GLANCE
We conducted serial arterial blood gas measurements in patients with COPD. Follow-up partial arterial pressure of oxygen (PaO 2 ) at 1 year in patients with mild hypoxaemia is clinically helpful since change in PaO 2 (ΔPaO 2 ) of -3.05 Torr/year predicts patients at risk of developing chronic respiratory failure within 6 years.
COPD, and identifying the factors associated with CRF development is of considerable importance.
However, little is known regarding the development of CRF and the trajectory of reductions in arterial oxygen in patients with COPD. As ventilation/perfusion ( Á V/ Á Q) mismatch resulting from airway obstruction, destruction of the pulmonary capillary bed and parenchymal destruction (emphysema) is the potential mechanism underlying the development of CRF in COPD, 7, 8 we hypothesized that physiological indices, such as forced expiratory volume in 1 s (FEV 1 ) and diffusing capacity, are closely associated with oxygenation and the future development of CRF. However, few studies have conducted sequential arterial blood gas (ABG) analysis, including partial arterial pressure of oxygen (PaO 2 ) assessments in patients with COPD, and the available data are inconsistent. 9 , 10 Saure et al. reported that individual PaO 2 trajectories fluctuate in patients with moderate-to-very severe COPD and no significant trends in PaO 2 were noted during a 3-year study period. These results suggest that longer periods of observation are required.
The purpose of the present study was to assess the trajectories of PaO 2 and identify the factors associated with changes in PaO 2 (ΔPaO 2 ) . We evaluated patients with 'mild hypoxaemia' (PaO 2 < 80 Torr) 11 who had already developed mild oxygenation impairment due to COPD and who were considered to be at higher risk for developing CRF with hypoxaemia. 10 
METHODS

Study design and subjects
Patients with stable COPD who visited Kyoto University Hospital from January 2006 to November 2008 and agreed to undergo ABG testing were recruited during exacerbation-free periods (no exacerbations in the previous 4 weeks). All the patients had a smoking history of ≥20 pack-years and were diagnosed based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. 12 Exclusion criteria are shown in Appendix S1 (Supplementary Information), including patients with a baseline PaO 2 < 60 Torr for the present study. We used data collected from this prospective cohort, which was approved by the ethics committee of Kyoto University (R0311-2), for post-hoc analysis. All cohort participants gave written or oral informed consent at recruitment before the start of the study.
Clinical and physiological examinations
The patients underwent a baseline pulmonary function test, ABG analysis and dyspnoea symptom assessment. The patients were then managed with standard treatments, including pharmacological treatments and non-pharmacological treatments, such as smoking cessation, and were given verbal recommendations regarding potential methods for increasing/maintaining their physical activity levels. The patients visited our outpatient clinic every 1 or 2 months during the postenrolment observation period and underwent serial pulse oximetry studies to determine whether they required LTOT. To evaluate the time courses of PaO 2 and other pulmonary functional parameters, we performed a second and/or third pulmonary function test and ABG analysis 1 year later (second assessment). All the baseline ABG analysis samples were collected after the patients had been sitting for 15 min. Arterial pH, PaO 2 and partial pressure of carbon dioxide (PaCO 2 ) were measured using a RAPIDlab 1265 Blood Gas Analyzer (Siemens Healthcare Diagnostics Inc., Malvern, PA, USA). CRF with hypoxaemia as outcome measure was diagnosed in patients who started LTOT. The date of LTOT initiation was recorded and analysed.
Statistical analysis
Changes in pulmonary function and ABG parameters during each assessment interval were calculated and are expressed as ΔPaO 2 (Torr/year). All statistical analyses were performed using JMP 11 software (SAS Institute Inc., Cary, NC, USA). Continuous variables are expressed as the mean AE SD, and categorical variables are expressed as numbers and percentages unless otherwise indicated. Correlations between pairs of variables were analysed using Pearson's correlation coefficient. Receiver-operating characteristic (ROC) curve analysis was performed to evaluate each parameter and to identify the optimal cut-off values for the prediction of the development of CRF with hypoxaemia during the observation period. Kaplan-Meier survival curves and the log-rank test were performed to show the associations between specific variables and the development of the conditions mentioned above, and both univariate and multivariate Cox proportional hazards analyses were conducted to clarify the relationships between the variables and the conditions. The Cox proportional hazards results are shown as hazard ratios (HR) with 95% CI. P-values less than 0.05 were considered statistically significant.
RESULTS
Patient characteristics
A total of 172 patients were enrolled in the present study and follow-up data for 164 of these patients are available (see Fig. S1 , Supplementary Information). The baseline characteristics of the patients are shown in Table 1 . At first, as we hypothesized that mild hypoxaemia is significant risk factor for the development of CRF, we compared patients with normal (≥80 Torr) and mild hypoxaemia (60 ≤ PaO 2 < 80 Torr) ( Table 1) . No patients with normal PaO 2 (≥80 Torr) developed CRF and 10 patients with mild hypoxaemia developed CRF within 6 years. Patients with mild hypoxaemia were significantly older, less likely current smokers and had more severe dyspnoea, lower FEV 1 and lower diffusing capacity of carbon monoxide (DL CO ) (P < 0.05). All patients who developed CRF with hypoxaemia were prescribed LTOT, mainly because of progressive resting hypoxaemia (PaO 2 < 55 Torr or percutaneous blood oxygen saturation (SpO 2 ) ≤ 88%). None of these patients had type 2 respiratory failure or were prescribed non-invasive positive-pressure ventilation at home.
Having mild hypoxaemia was a significant risk factor for developing CRF compared with patients with normal PaO 2 at baseline (log-rank test, P < 0.01). Among mild hypoxaemic patients, patients who developed CRF with hypoxaemia had a lower baseline diffusing capacity (%DL CO or carbon monoxide transfer coefficient (K CO )), a lower baseline PaCO 2 and a higher baseline A-aDO 2 (alveolar-arterial oxygen tension difference) than patients who did not develop CRF (P < 0.05; see Table S1 , Supplementary Information). In addition, no females or current smokers at baseline developed CRF during follow-up; therefore, these factors had no significant impact on the development of CRF (log-rank test, P = 0.23 and 0.22, respectively).
Following these crude investigations, we decided to analyse the data of only the patients with mild hypoxaemia at baseline because we intended to assess the data related to the development of CRF (see Table S2 , Supplemental Information).
ΔPaO 2 in COPD patients with mild hypoxaemia Figure 1 shows the distributions of the changes in PaO 2 from baseline to 1-year follow-up (ΔPaO 2 ) in 1 year in patients with mild hypoxaemia. ΔPaO 2 was normally but widely distributed (see Table S3 (Supplemental Information), mean AE SD: 1.43 AE 5.44 Torr/year). The maximal decline was −11.4 Torr/year, and the maximal increase was 13.5 Torr/year. There was no significant trend in PaO 2 according to each GOLD spirometric stage (Fig. 2A) ; however, the ΔPaO 2 in 1 year was significantly associated with baseline K CO and %FRC (r = 0.26 and −0.22, respectively) (Fig. 2B) . Patients with high K CO (≥ the mean + 1/2 SD) had significantly high ΔPaO 2 than others; moreover, most patients with high K CO showed increased PaO 2 in 1 year.
ROC analysis
We performed ROC analysis using data from the patients with mild hypoxaemia (see Appendix S1, Fig. S2, Supplementary Information) . ROC analysis showed that a ΔPaO 2 of −3.05 Torr/year and a K CO of 2.15 mL/min/L/mm Hg were the optimal cut-off values for developing CRF with hypoxemia during the 6-year follow-up period.
Survival and risk analyses in COPD patients with mild hypoxaemia
The Kaplan-Meier survival analysis, in which the patients were stratified according to the optimal cut-off values for ΔPaO 2 in 1 year (Fig. 3A) and baseline K CO (Fig. 3B) showed that patients with a ΔPaO 2 ≥ −3.05 Torr/year had a significantly higher risk of developing CRF within 6 years than patients with a ΔPaO 2 < −3.05 Torr/year (HR: 12.6, 95% CI: 3.48-58.73, P < 0.0001, by log-rank test). To clarify the relationships between the clinical parameters mentioned above and the rates of specific events, we performed Cox proportional hazards analysis using three models including various parameters, such as %FEV 1 , K CO , %FRC, baseline PaO 2 and prior exacerbations. After univariate analysis (Table 2) , we tested three multivariate models (Table 3 ). In the univariate analyses, %FEV 1 , K CO and ΔPaO 2 in 1 year were highly significant predictors of CRF (Table 2 ). In the multivariate analyses, model 1 is composed of items that exhibited a strong relationship (P < 0.01) with CRF development in the univariate analyses, and models 2 and 3 include items that are believed to be predictors of hypoxaemic respiratory failure in COPD based on the results of previous reports. ΔPaO 2 and K CO were significantly associated with CRF development in all the models (Table 3) .
DISCUSSION
We investigated the natural course of patients with COPD for 6 years from our prospective cohort study and found that having mild hypoxaemia (PaO 2 < 80 Torr) and a low K CO at baseline may be significant predictors of the development of CRF with hypoxaemia requiring LTOT. In addition, a short-term (1 year) decline in PaO 2 may be associated with further declines in PaO 2 . The data show that −3.0 Torr/year of ΔPaO 2 was a clinically significant threshold. To our knowledge, this is the first report to show that shortterm serial PaO 2 assessments in patients with COPD may have potential to predict the eventual (within 6 years) development of CRF.
ΔA-aDO 2 (change in A-aDO 2 ) was also significantly associated with CRF development. However, the prediction capability of ΔA-aDO 2 for CRF development was inferior to that of ΔPaO 2 . Like ΔPaO 2 , a deteriorating diffusing capacity at baseline is also a good predictor of CRF development. The results indicate that patients with stable COPD and mild hypoxaemia (PaO 2 < 80 Torr) and a lower diffusing capacity (K CO ) will benefit from ABG assessments after 1 year and that patients showing larger (≥3.0 Torr/year) declines in PaO 2 have a 12-fold higher risk of developing CRF within 6 years.
As diffusing capacity is one of the key functional indexes of gas exchange in the lung, it is unsurprising that diffusing capacity was strongly correlated with PaO 2 at baseline (Table  S1 , Supplemental Information). [13] [14] [15] Parenchymal destruction (emphysema) is associated with deteriorating diffusing capacity [16] [17] [18] and the subsequent development of Á V/ Á Q mismatches. 19 As expected, baseline K CO was the strongest determinant of PaO 2 at baseline (Table S1 , Supplemental Information). However, the predictors of future deterioration in diffusing capacity and PaO 2 are unknown. Moreover, whether short-term declines in PaO 2 are predictive of long-term deterioration in PaO 2 are also unknown. The presence of significant relationships between functional parameters and longitudinal PaO 2 trajectories in patients with COPD is one of the novel findings from the present study. Moreover, these results are consistent with our report showing that diffusing capacity is a significant prognostic factor in male patients with stable COPD, 20 and that emphysema severity, which is closely associated with diffusing capacity, is a significant prognostic factor identified in numerous cohort studies, including our previous study. 21 Our findings suggest that patients with a low K CO should be closely observed and undergo serial assessments of physiological parameters, including PaO 2 .
The length of observation needed regarding ABG, including PaO 2 , remains unclear; however, our results indicate that a 1-year observation period is sufficient to predict further deterioration within 6 years into CRF, with −3.0 Torr/year a significant threshold value. Our findings also indicate that K CO is a good marker for predicting hypoxaemia progression. ABG analysis is more widely available to general physicians than are diffusing capacity measurement tools and repeat ABG measurements may be an alternative means of predicting PaO 2 trajectories. Whether changes in SpO 2 can be substituted for changes in PaO 2 is an interesting question. Importantly, small changes in PaO 2 may be impossible to detect precisely using SpO 2.
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With the exception of recent studies by Saure et al., there are no studies of serial ABG evaluations and PaO 2 decline in patients with COPD. The results of our study are generally consistent with those of previous reports, which indicated that PaO 2 values fluctuate (ranged from 13.5 to −11.4 Torr/year); however, trends in PaO 2 demonstrated by multiple measurements can be used to estimate the risk of all-cause mortality. 9, 23 This study had several limitations. First, the sample size was small, and the study was conducted in a single centre. Second, only 10 patients developed CRF during the 6-year follow-up period, and no current smokers at baseline or female patients developed CRF. Although log-rank tests used to assess gender and smoking status at baseline did not show statistical significance, these confounding factors should be considered in the present study. To clarify this issue, we also conducted Cox regression sub-analyses for males and former smokers (n = 81) and found similar (or even stronger) results (Tables S4,S5 , Supplementary Information). Third, we hypothesized that image analysis may provide additional information, because we previously reported that CT parameters, such as emphysema severity (percentage of low attenuation area; LAA%), were associated with mortality in patients with COPD. 24, 25 However, we could not find any significant associations between LAA% and patient outcomes (data not shown). This negative result may be attributable to missing CT data and discrepancies in structure-function relationships. In our previous study, physical activity was significantly associated with diffusing capacity but not with LAA%. 26 Fourth, we could not find an explanation for why ΔA-aDO 2 was not a better index than ΔPaO 2 . Regarding Á V/ Á Q mismatch, we expected ΔA-aDO 2 to be associated more strongly with CRF development. It is likely that the small sample size and the wide and non- ) and patients with low K CO values (≤2.15 mL/min/L/mm Hg, n = 37, ) (log-rank P < 0.01). ΔPaO 2 , change PaO 2 ; CRF, chronic respiratory failure; K CO , carbon monoxide transfer coefficient; PaO2, partial arterial pressure of oxygen. Model 1 included the top three items that were significantly associated with CRF development in the present study. Model 2 included items associated with the development of hypoxaemia that were reported in Saure et al. 9 Model 3 included items associated with the development of hypoxaemia that were reported in Wells et al. ; ΔRV, change in RV; ΔVC, change in VC; A-aDO 2 , alveolar-arterial oxygen tension difference; CRF, chronic respiratory failure; DL CO , diffusing capacity of carbon monoxide; FEV 1 , forced expiratory volume in 1 s; FRC, functional residual capacity; FVC, forced vital capacity; HR, hazard ratio; K CO , carbon monoxide transfer coefficient; LABA, long-acting β 2 -agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified British Medical Research Council; PaCO 2 , partial pressure of carbon dioxide; PaO 2 , partial arterial pressure of oxygen; RV, residual volume; TLC, total lung capacity; VC, vital capacity.
normal distribution of ΔA-aDO 2 (see Fig. S3 , Supplementary Information) are the reasons for this finding. Fifth, we mainly enrolled patients with mild hypoxaemia, because we hypothesized that mild hypoxaemia is a significant risk factor for developing CRF. To apply our findings to all patients with COPD, we need to extend our cohort study to longer periods or larger sample sizes.
In conclusion, this study provided new and important information indicating that K CO predicts longitudinal PaO 2 changes and CRF within 6 years. Serial measurements in PaO 2 also have the potential to predict CRF. Table S4 Univariate Cox proportional hazards analysis of the relationships between CRF development and baseline parameters or changes in parameters in male former smokers (n = 81). Table S5 Multivariate Cox proportional hazards analysis of the parameters associated with CRF development in male former smokers (n = 81). Visual Abstract Annual PaO2 changes and chronic respiratory failure in COPDA six-year follow-up study.
